Navigation Links
Questcor Pharmaceuticals to Present at Investor Conferences in September
Date:9/5/2012

ANAHEIM, Calif., Sept. 5, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive management will present at the following investor conferences in September 2012:

  • Morgan Stanley Global Healthcare Conference in New York City on September 11, 2012 at 3:30 PM ET.
  • G9: ThinkEquity's 9th Annual Growth Conference in New York City on September 12, 2012 at 3:30 PM ET.

A live webcast and subsequent archived replay of the presentations will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for approximately 90 days after the event.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor has launched a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... Mass. , Sept. 1, 2017 ... HealthCare Solutions, Inc , highlights opportunities for growth in ... Journal report that Marlin Equity is seeking a buyer ... an annual award-winning 22-year-old healthcare solutions Value Added Reseller ... "As the healthcare ...
(Date:9/1/2017)... Sept. 1, 2017  Bayer will present the latest research ... for Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... new preclinical and clinical data on Bayer,s marketed portfolio and ... projects. "We value ... in cancer research at ESMO," said Carsten Brunn , ...
(Date:8/29/2017)... ivWatch, LLC, the leading provider of continuous monitoring devices ... been awarded an Innovative Technology contract from Vizient, Inc., the largest ... ... the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short ... has already been receiving positive feedback from customers trying the product for the first ... Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes ...
(Date:9/20/2017)... ... 2017 , ... Five consumer packaged goods (CPG) products were selected by the ... Nopavera Plus was named to the short list in the Specialty Supplements ... during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort ...
(Date:9/20/2017)... ... September 20, 2017 , ... Medicare doesn’t ... risk of price gouging for their prescription drugs, according to a new comparison ... isn’t negotiating on our behalf, there’s no consistency in drug pricing among drug ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... poor, the new feel good program from Leany Greeny delivers positive results in ... can rejuvenate overall health and kickstart the metabolism. Fitting seamlessly into hectic work ...
(Date:9/20/2017)... ... September 20, 2017 , ... “RECYCLED ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION” is the creation of published author, ... field of addiction and homeless services, including more than a decade of addiction ...
Breaking Medicine News(10 mins):